1. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized Open-Label Trial
- Author
-
Kempapura Murthy, Sarah Spencer, Holly C Groom, Sara S Kim, Laura J. Edwards, Zuha Jeddy, Lauren Beacham, F. Liaini Gross, Fatimah S. Dawood, Edward A. Belongia, Shivaprakash Gangappa, Allison L. Naleway, Meredith G Wesley, Min Z. Levine, Sarah Ball, Margarita Mishina, Mark G. Thompson, Suryaprakash Sambhara, Danielle R. Hunt, Weiping Cao, Alicia M. Fry, Manjusha Gaglani, Brendan Flannery, and Kelsey R. Bounds
- Subjects
Microbiology (medical) ,Influenza vaccine ,Population ,Cell Culture Techniques ,immunogenicity ,Antibodies, Viral ,law.invention ,Immunogenicity, Vaccine ,Influenza A Virus, H1N1 Subtype ,cohort studies ,Randomized controlled trial ,law ,Influenza, Human ,Major Article ,Humans ,Medicine ,Seroconversion ,education ,education.field_of_study ,Hemagglutination assay ,business.industry ,Influenza A Virus, H3N2 Subtype ,Immunogenicity ,COVID-19 ,Hemagglutination Inhibition Tests ,Virology ,Vaccination ,Influenza B virus ,Titer ,AcademicSubjects/MED00290 ,Infectious Diseases ,Vaccines, Inactivated ,Influenza Vaccines ,business ,Delivery of Health Care ,healthcare personnel - Abstract
Background RIV4 and cell-culture based inactivated influenza vaccine (ccIIV4) have not been compared to egg-based IIV4 in healthcare personnel, a population with frequent influenza vaccination that may blunt vaccine immune responses over time. We conducted a randomized trial among healthcare personnel (HCP) aged 18–64 years to compare humoral immune responses to ccIIV4 and RIV4 to IIV4. Methods During the 2018–2019 season, participants were randomized to receive ccIIV4, RIV4, or IIV4 and had serum samples collected prevaccination, 1 and 6 months postvaccination. Serum samples were tested by hemagglutination inhibition (HI) for influenza A/H1N1, B/Yamagata, and B/Victoria and microneutralization (MN) for A/H3N2 against cell-grown vaccine reference viruses. Primary outcomes at 1 month were seroconversion rate (SCR), geometric mean titers (GMT), GMT ratio, and mean fold rise (MFR) in the intention-to-treat population. Results In total, 727 participants were included (283 ccIIV4, 202 RIV4, and 242 IIV4). At 1 month, responses to ccIIV4 were similar to IIV4 by SCR, GMT, GMT ratio, and MFR. RIV4 induced higher SCRs, GMTs, and MFRs than IIV4 against A/H1N1, A/H3N2, and B/Yamagata. The GMT ratio of RIV4 to egg-based vaccines was 1.5 (95% confidence interval [CI] 1.2–1.9) for A/H1N1, 3.0 (95% CI: 2.4–3.7) for A/H3N2, 1.1 (95% CI: .9–1.4) for B/Yamagata, and 1.1 (95% CI: .9–1.3) for B/Victoria. At 6 months, ccIIV4 recipients had similar GMTs to IIV4, whereas RIV4 recipients had higher GMTs against A/H3N2 and B/Yamagata. Conclusions RIV4 resulted in improved antibody responses by HI and MN compared to egg-based vaccines against 3 of 4 cell-grown vaccine strains 1 month postvaccination, suggesting a possible additional benefit from RIV4., In this randomized trial among healthcare personnel comparing antibody responses to cell-culture based and recombinant influenza vaccines (RIV4) versus standard-dose egg-based vaccines, RIV4 recipients had higher antibody responses against 3 cell-grown vaccine strains suggesting a possible additional benefit from RIV4.
- Published
- 2021
- Full Text
- View/download PDF